NCT03949426 - Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

September 29, 2019

Study Completion Date

September 29, 2019

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

KPG-818

KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.

Trial Locations (1)

91206

California Clinical Trials Medical Group, Glendale